Klaria Interim Report Q3 2020
Klaria Interim Report Q3 2020
Summary of the period
Two new clinical programs initiated, first license agreement signed inthe medical cannabis segment
THIRD QUARTER 2020 (JULY–SEPTEMBER)
Net sales amounted to 0.0 MSEK (0.1 MSEK)
R&D costs for the period amounted to 13.6 MSEK (5.4 MSEK)
Profit after tax amounted to -13.3 MSEK (-7.2 MSEK)
Earnings per share for the quarter amounted to -0.28 SEK (-0.23 SEK)
Cash flow from operating activities amounted to -12.2 MSEK (5.5 MSEK)
Cash and cash equivalents on the balance day amounted to 19.3 MSEK (8.9 MSEK)
Shareholder’s equity per September 30, amounted to 104.5 MSEK (87.5 MSEK)
THE PERIOD JANUARY–SEPTEMBER 2020
Net sales amounted to 0.0 MSEK (4.0 MSEK)
R&D costs for the period amounted to 30.8 MSEK (14.5 MSEK)
Profit after tax amounted to -34.4 MSEK (-17.2 MSEK)
Earnings per share for the quarter amounted to -0.83 SEK (-0.56 SEK)
Cash flow from operating activities amounted to -25.2 MSEK (-9.1 MSEK)
On February 24, 2020, the merger between Karessa Pharma Holding AB (publ) and Klaria Pharma Holding AB (publ), that received approval at extraordinary general meetings in the two companies, was completed. The merger was registered at Bolagsverket as of March 6, 2020, and Karessa is thereby dissolved. The terms for the merger was that one share in Karessa was exchanged for 0.6032 new shares in Klaria. In connection with the merger, 6,035,200 new shares in Klaria were issuedto Karessa’s shareholders. After the merger has been completed, the number of shares in Klaria amounts to 38,728,448.
The company raised 11.4 MSEK through a directed issue of 3,800 shares at a price of 3 SEK per share.
EVENTS AFTER THE END OF THE PERIOD
At an extraordinary general meeting on November 2, the board decided to issue a maximum of 4,239,766 shares to an international consortium at a share price of 6.84 SEK, which will provide the company with amaximum of 29 MSEK. After the decision of the share issue, the number of shares in the company will amount to a maximum of 52,466,174 and the share capital will amount to a maximum of 874,436.23 SEK.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.